002581 *ST未名医药
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-2.974-6.176-6.879-14.929-0.614
总资产报酬率 ROA (%)-2.547-5.329-6.058-12.770-0.521
投入资产回报率 ROIC (%)-2.849-5.887-6.645-14.132-0.566

边际利润分析
销售毛利率 (%)13.51852.84279.78580.59678.657
营业利润率 (%)-133.222-65.134-30.930-68.2559.430
息税前利润/营业总收入 (%)-134.201-64.965-41.749-71.1785.609
净利润/营业总收入 (%)-132.666-58.525-39.632-74.952-0.240

收益指标分析
经营活动净收益/利润总额(%)71.32283.27852.37557.758-1,464.805
价值变动净收益/利润总额(%)26.502-9.585-42.915-55.1261,708.919
营业外收支净额/利润总额(%)0.508-1.97223.7416.352-164.616

偿债能力分析
流动比率 (X)3.6543.2999.0433.7181.423
速动比率 (X)2.8862.8108.0793.0791.203
资产负债率 (%)8.89010.2387.9066.99213.571
带息债务/全部投入资本 (%)2.7183.2640.3910.5667.092
股东权益/带息债务 (%)3,532.6862,927.52624,345.70017,332.7481,296.269
股东权益/负债合计 (%)970.987829.8421,108.0081,265.802612.512
利息保障倍数 (X)448.44959.57635.077-41.7192.742

营运能力分析
应收账款周转天数 (天)528.645222.388103.234125.947211.052
存货周转天数 (天)249.216240.136407.533356.911340.998